Question

I am a breastfeeding mother and i want to know if it is safe to use Pioglitazonum [INN-Latin]? Is Pioglitazonum [INN-Latin] safe for nursing mother and child? Does Pioglitazonum [INN-Latin] extracts into breast milk? Does Pioglitazonum [INN-Latin] has any long term or short term side effects on infants? Can Pioglitazonum [INN-Latin] influence milk supply or can Pioglitazonum [INN-Latin] decrease milk supply in lactating mothers?

Pioglitazonum [INN-Latin] lactation summary

Pioglitazonum [INN-Latin] usage has low risk in breastfeeding
  • DrLact safety Score for Pioglitazonum [INN-Latin] is 3 out of 8 which is considered Low Risk as per our analyses.
  • A safety Score of 3 indicates that usage of Pioglitazonum [INN-Latin] may cause some minor side effects in breastfed baby.
  • Our study of different scientific research indicates that Pioglitazonum [INN-Latin] may cause moderate to no side effects in lactating mother.
  • Most of scientific studies and research papers declaring usage of Pioglitazonum [INN-Latin] low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
  • While using Pioglitazonum [INN-Latin] We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
  • Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Answer by Dr. Ru: About Pioglitazonum [INN-Latin] usage in lactation

Tiazolidindion drugs increase response to insulin.Oral anti-diabetic drugs are useless as treatment of diabetes type 1. For diabetes type 2, diet and exercise are advisable. Breastfeeding helps to lower glucemia level. See section on Maternal diabetes mellitus

Answer by DrLact: About Pioglitazonum [INN-Latin] usage in lactation

No information is available on the clinical use of Pioglitazonum [INN-Latin] during breastfeeding. Pioglitazonum [INN-Latin] is over 99% protein bound in plasma, so it is unlikely to pass into breastmilk in clinically important amounts. If Pioglitazonum [INN-Latin] is required by the mother, it is not a reason to discontinue breastfeeding. However, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.